---
title: "NICE Actimize Positioned as a Luminary in Celent’s 2026 “Know Your Customer Systems: Adverse Media Screening” Report"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293931421.md"
description: "NICE Actimize, a division of NiCE (NASDAQ: NICE), was acknowledged by Celent, a respected global research and advisory firm for financial services, as a top performer in their report \"Know Your Customer Systems: Adverse Media Screening Technology Capabilities Matrix.\" Among 25 providers evaluated, NICE Actimize was classified as a Luminary, representing excellence in KYC/Adverse Media solutions. This recognition highlights the company's advanced technology and functionality in this area."
datetime: "2026-07-27T12:03:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293931421.md)
  - [en](https://longbridge.com/en/news/293931421.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293931421.md)
generator: "portal-rs"
---

# NICE Actimize Positioned as a Luminary in Celent’s 2026 “Know Your Customer Systems: Adverse Media Screening” Report

NICE Actimize, a division of NiCE (NASDAQ: NICE), was acknowledged by Celent, a respected global research and advisory firm for financial services, as a top performer in their report "Know Your Customer Systems: Adverse Media Screening Technology Capabilities Matrix." Among 25 providers evaluated, NICE Actimize was classified as a Luminary, representing excellence in KYC/Adverse Media solutions. This recognition highlights the company's advanced technology and functionality in this area.

### Related Stocks

- [NICE.US](https://longbridge.com/en/quote/NICE.US.md)

## Related News & Research

- [NICE releases 2025 ESG report, posts 23% cut in Scope 1 and 2 emissions](https://longbridge.com/en/news/298437306.md)
- [NICE says AOK PLUS goes live on its CX AI platform](https://longbridge.com/en/news/298315861.md)
- [AI Expands Strategic Role of Contact Centers, ISG Says | III Stock News](https://longbridge.com/en/news/298609566.md)
- [NICE (TASE:NICE) Wins Bluecrest Deal After AI Narrative Puts Valuation Back In Focus](https://longbridge.com/en/news/297414050.md)
- [HIV charities lament NICE snub for Gilead’s twice-yearly lenacapavir](https://longbridge.com/en/news/298763671.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**